Research Articles

2023

Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion-Mutated Breast Cancer. O'Neil SR, Weber GA, Deming DA, Burkard ME, Kenny PA, Richmond CS & Parsons BM (2023) JCO Precision Oncology  7:e2300174  [PDF].

Grb7 knockout mice develop normally but litters born to knockout females fail to thrive. Lofgren KA & Kenny PA (2023) Developmental Dynamics (in press, published on line 12/23/2023).  [PDF].

Mammary-specific ectopic expression of mutant human GATA3 did not potentiate medroxyprogesterone acetate-driven mouse mammary tumorigenesis. Lofgren KA & Kenny PA (2023) bioRxiv  2023.01.03.522644  [PDF].

2022

Optimized infection control practices augment the robust protective effect of vaccination for ESRD patients during a hemodialysis facility SARS-CoV-2 outbreak (2022) Meller ME, Pfaff BL, Borgert AJ, Richmond CS, Athas DM, Kenny PA, Sabin AP. American Journal of Infection Control 50(10):1118-1124. [PDF].

Pan-cancer distribution of cleaved cell-surface Amphiregulin, the target of the GMF-1A3 antibody drug conjugate. Lofgren KA, Reker NC, Sreekumar S, Kenny PA (2022) bioRxiv 2022.03.10.483840 [PDF].

Acquisition and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient. Sabin AP, Richmond CS, Kenny PA (2022) Diagnostic Microbiology & Infectious Disease 103(1):115656 [PDF].

2021

Anti-tumor efficacy of an MMAE conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer. Lofgren KA, Sreekumar S, Jenkins EC, Ernzen KJ, Kenny PA (2021) Antibody Therapeutics 4(4):252-261 [PDF].

Outbreak or pseudo-outbreak? Integrating SARS-CoV-2 sequencing to validate infection control practices in an end stage renal facility. Pfaff BL, Richmond CS, Sabin AP, Athas DM, Adams JC, Meller ME, Usha K, Schmitz SA, Simmons BJ, Borgert AJ, Kenny PA (2021) American J Infection Control 49(10);1232-1236 [PDF].

Melanomagenesis driven by a kinase-dead mutant BRAF lacking codons 600-618. Girtman MA, Richmond CS, Campbell ME, Rehrauer WM, Kenny PA (2021) bioRxiv 2021.08.20.457149 [PDF].

The MKRN1-BRAF fusion is a targetable oncogenic driver. Girtman MA, Richmond CS, Kenny PA (2021) bioRxiv 2021.07.22.453427 [PDF].

2020

SARS-CoV-2 sequencing reveals rapid transmission from college student clusters resulting in morbidity and death in vulnerable populations. Richmond CR, Sabin AP, Jobe DA, Lovrich SD, Kenny PA (2020) medRxiv 2020.10.12.20210294 [PDF]

Interregional SARS-CoV-2 spread from a single introduction outbreak in a meat-packing plant in northeast Iowa. Richmond CR, Sabin AP, Jobe DA, Lovrich SD, Kenny PA (2020) medRXiv 2020.06.08.20125534 [PDF]

Acquisition of cabozantinib-sensitive MET D1228N mutation during progression on crizotinib in MET-amplified triple-negative breast cancer. Parsons BM, Meier DR, Richmond CS, Gurda GT, Burkard ME, Deming DA, Kenny PA (2020) Clinical Breast Cancer 20(4):e433-438 [PDF]

Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice. Meier DR, Girtman MA, Lofgren KA, Kenny PA. (2020) Breast Cancer Research & Treatment 179:653-660. [PDF]

2019

InferAMP, a python web app for copy number inference from discrete gene-level amplification signals noted in clinical tumor profiling reports. Kenny PA (2019) F1000 Research 8:807 [PDF]

Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma. Richmond CS, Vallatharasu Y, Deviley JA, Vos CR, Parsons BM, Kenny PA (2019)  Experimental & Molecular Pathology [PDF]

MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers. Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, Parsons BM, Kenny PA, Matkowskyj KA, Newton MA, Skala MC, Deming DA (2019)  Molecular Cancer Therapeutics 18(2):346-355 [PDF] [Cited by 1]

2018

Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells. Emmanuel N, Lofgren KA, Peterson EA, Meier DR, Jung EH, Kenny PA (2018)  Anticancer Research (38)4435-4441 [PDF]

Adaptation of an amplicon-based human cancer next-generation sequencing panel assay for murine tumors.  Meier DR, Lofgren KA, Gurda GT, Kenny PA (2018) Analytical Biochemistry 551:26-28 [PDF]

Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth. Mao SPH, Park M, Cabrera RM, Christin JR, Karagiannis GS, Oktay MH, Zaiss DMW, Abrams SI, Guo W, Condeelis JS, Kenny PA, Segall JE (2018)  Breast Cancer Research 26;20(1):131 [PDF]

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shelloe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma A (2018)  JCI Insight 3(14):e120422 [PDF]

Assessment of the TRPM8 inhibitor AMTB in breast cancer cells and its identification as an inhibitor of voltage gated sodium channels. Yapa KT, Deuis J, Peters AA, Kenny PA, Roberts-Thomson SJ, Vetter I, Monteith GR (2018)  Life Sci. 198:128-135.[PDF] [Cited by 4]

2017

Exceptional response to crizotinib in an MET-amplified triple-negative breast tumor.  Parsons BM, Meier DR, Gurda GT, Lofgren KA & Kenny PA. Journal of Clincal Oncology - Precision Oncology [PDF] [Cited by 2]

Genomic analysis of melanoma evolution following a 30-year disease-free interval. Miller JJ, Lofgren KA, Hughes SR, Cash SE & Kenny PA.  Journal of Cutaneous Pathology 44(9):805-808. [PDF]

Implementation and clinical utility of an integrated academic-community regional molecular tumor board. Burkard ME, Deming DA, Parsons BM, Kenny PA, Schuh MR, Leal T, Uboha N, Lang JM, Thompson MA, Warren R, Bauman J, Mably MS, Laffin J, Paschal CR, Lager AM, Lee K, Matkowskyj KA, Buehler DG, Rehrauer WM, Kolesar J.  Journal of Clinical Oncology - Precision Oncology [PDF] [Cited by 9]

Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells. Peters AA, Jamaludin SY, Kunsala YT, Chalmers S, Wiegmans AP, Huai LF, Milevskiy MJ, Azimi I, Davis FM, Northwood KS, Pera E, Marcial DL, Dray E, Waterhouse NJ, Cabot PJ, Gonda TJ, Kenny PA, Brown MA, Khanna KK, Roberts-Thomson SJ and Monteith GR (2017) Oncogene 36(46):6490-6500. [PDF] [Cited by 13]

2016

An instructive ductal microenvironment is key for efficient in vivo modeling of estrogen receptor positive breast cancer. Lofgren KA and Kenny PA (2016)  Translational Cancer Research 5:S2:S360-362 [PDF].

Altered purinergic receptor-Ca2+ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells. Azimi I, Beilby H, Davis FM, Marcial DL, Kenny PA, Thompson EW, Roberts-Thomson SJ & Monteith GR (2016)  Molecular Oncology 10(1):166-178 [PDF] [Cited by 36]

2015

Amphiregulin is a critical downstream effector of estrogen signaling in ERa-positive breast cancer. Peterson EA, Jenkins EC, Lofgren KA, Chandiramani N, Liu H, Aranda E, Barnett M, Kenny PA (2015) Cancer Research 75(22):4830-4838 [PDF] [Cited by 20]

2014

Comparative analysis of GATA3 mutation profiles between Asian and Western breast cancer patients: Is there really a difference? Chandiramani N and Kenny PA (2014)  Cancer 120(17)2778-2779 [PDF].

Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo. Zhou ZN, Sharma VP, Beaty, BP, Roh-Johnson M, Peterson EA, Van Rooijen N, Kenny PA, Wiley HS, Condeelis JS and Segall JE (2014)  Oncogene 33(29):3784-3793 [PDF] [Cited by 77].

PI3K-Akt signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis. So PL, Wang GY, Wang K, Chuang M, Chiueh  VC, Kenny PA and Epstein EH (2014)  Cancer Prevention Research 7(4):407-17 [PDF] [Cited by 8]

2013

Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls. Peterson EA, Pectasides E, Shabbeer S, Wiechmann L, Sparano JA & Kenny PA. (2013)  Experimental Hematology & Oncology 2(1):25 [PDF] [Cited by 3]

Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer. Miwa HE, Koba WR, Fine EJ, Giricz O, Kenny PA & Stanley P. (2013)  Glycobiology 23(12):1477-1490 [PDF] [Cited by 23].

TACE-dependent TGF-alpha shedding drives triple-negative breast cancer cell invasion. Giricz O, Calvo V, Peterson EA, Abouzeid CM and Kenny PA (2013)  International Journal of Cancer 133:2587-2595 [PDF] [Cited by 33].

Visualizing movement in the tumor microenvironment landscape. Calvo V and Kenny PA. (2013)  Breast Cancer Research 15:301. [PDF] [Cited by 3]

Mitochondrial calcium uniporter silencing potentiates caspase-independent cell death in MDA-MB-231 breast cancer cells. Curry MC, Peters AA, Kenny PA, Roberts-Thomson SJ and Monteith GR (2013)  Biochem Biophys Res Comm434(3):695-700. [PDF] [Cited by 54]

miR-21 mediates hematopoietic suppression in MDS by activating TGF-b signaling. Bhagat TD, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati K, Steidl U, Stein C, Ju W, Liu G, Kenny PA, List A, Bitzer M and Verma A. (2013)  Blood 121(15):2875-81. [PDF] [Cited by 83].

Translating genomic research into clinical practice: Promises and pitfalls. Sparano JA, Ostrer H and Kenny PA (2013)  ASCO Educational Book 15-23 [PDF] [Cited by 9]

2012

Clarification of the C-terminal proteolytic processing site of human Amphiregulin. Levano KS and Kenny PA (2012)  FEBS Letters 586(19):3500-2. [PDF] [Cited by 6].

Normal range of serum Amphiregulin in healthy adult human females. Peterson EA, Shabbeer S and Kenny PA (2012)  Clin Biochem 43:460-463 [PDF] [Cited by 10].

Hsa-miR-375 Is Differentially Expressed During Breast Lobular Neoplasia And Promotes Loss Of Mammary Acinar Polarity. Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, Childs G, Shapiro N, Fineberg S, Kenny PA and Loudig O. (2012)  Journal of Pathology 226:108-119 [PDF]. [Cited by 70]

GRB7 is required for triple-negative breast cancer cell invasion and survival. Giricz O, Calvo V, Pero SC, Krag DN, Sparano JA and Kenny PA. (2012)  Breast Cancer Research and Treatment 133:607-615 [PDF] [Cited by 40].

Selective gene expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Patsialou A, Wang Y, Lin J, Whitney K, Goswami S, Kenny PA and Condeelis JS. (2012).  Breast Cancer Research 14(5):139 [PDF] [Cited by 95].

FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. Lee SY, Meier R, Furuta S, Lenburg ME, Kenny PA, Xu R and Bissell MJ (2012)  Journal Of Clinical Investigation [PDF] [Cited by 62]

Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor negative breast cancer. Peters AA, Simpson PT, Bassett JJ, Lee JM, Da Silva L, Reid LE, Song S, Parat MO, Lakhani SR, Kenny PA, Roberts-Thomson SJ and Monteith GR (2012)  Mol Cancer Therapeutics (10):2158-68. [PDF] [Cited by 64]

Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells. Curry MC, Luk NA, Kenny, PA, Roberts-Thomson SJ and Monteith GR. (2012)  J Biol Chem 287(34):28598-28608 [PDF] [Cited by 50]

Peroxisome proliferator-activated receptor subtypes in mammary gland development and breast cancer. Falconer C, Kenny PA, Smart CE, Monteith GR, Roberts-Thomson S (2012) Peroxisome proliferator-activated receptor subtypes in mammary gland development and breast cancer. J Cancer Therapeutics & Research 1:14 [PDF] [Cited by 2].

2011

Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines. Levano KS, Jung EH and Kenny PA (2011)  Biochem Biophys Res Comm 411 107-110 [PDF] [Cited by 26]

Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple negative breast cancer. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW and Gray R . (2011)  Clinical Cancer Research 17(22):7194-7203 [PDF] [Cited by 17].

Illumina Whole-Genome DASL Platform: Assessing Its Performance in Formalin-Fixed Paraffin-Embedded Samples and Its Applicability for Identification of Invasion-Related Genes in Aggressive Oral Squamous Cell Carcinoma. Loudig O, Brandwein-Gensler M, Kim R, Lin J, Isayeva T, Segall JE, Kenny PA and Prystowsky MB (2011)  Human Pathology 42(12):1911-22 [PDF] [Cited by 25].

Remodeling of Purinergic Receptor-Mediated Ca2+ Signaling as a Consequence of EGF-Induced Epithelial-Mesenchymal Transition in Breast Cancer Cells. Davis FM, Kenny PA, Soo ETL, van Denderen BJW, Thomson EW, Cabot PJ, Parat MO, Roberts-Thomson SJ and Monteith GR. (2011)  PLOS One 6(8): e23464 [PDF] [Cited by 43].

ORAI1-mediated calcium influx in lactation and breast cancer. McAndrew D, Grice DM, Peters AA, Davis FM, Stewart T, Rice M, Smart CE, Brown MA, Kenny PA, Roberts-Thomson SJ and Monteith GR (2011)  Mol Cancer Therapeutics 10(3):448-60 [PDF] [Cited by 132]

2010

Store-Independent Activation of Orai1 by SPCA2 in Mammary Tumors. Feng M, Grice DM, Faddy HM, Nguyen N, Leitch S, Wang Y, Muend S, Kenny PA, Sukumar S, Roberts-Thomson S, Monteith G and Rao R (2010)  Cell (143) 84-98 [PDF ][Cited by 195]

Clinical application of gene expression profiling in breast cancer. Sparano JA, Fazzari M and Kenny PA (2010)  Surgical Oncol Clinics North America (19):581-606. [PDF] [Cited by 25]

The golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231. Grice DM, Vetter I, Faddy HM, Kenny PA, Roberts-Thomson SJ, and Monteith GR (2010).  J Biol Chem 285(48):37458-66 [PDF] [Cited by 95]

Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. Han J, Chang H, Giricz O, Lee GY, Baehner FL, Gray JW, Bissell MJ, Kenny PA and Parvin B.  Plos Computational Biology 6(2) e1000684 [PDF] [Cited by 80]

2009

Endothelial cell migration and VEGF expression are the result of loss of breast tissue polarity. Chen A, Cuevas I, Kenny PA, Miyake H, Mace K, Ghajar C, Boudreau A, Bissell MJ and Boudreau N (2009).  Cancer Research 69(16):6721-6729. [PDF] [Cited by 46]

2008

Localization of plasma membrane and secretory calcium pumps in the mammary gland.  Faddy HM, Smart CE, Xu R, Lee GY, Kenny PA, Feng M, Rao R, Brown MA, Bissell MJ, Roberts-Thomson SJ and Monteith GR (2008). Biochem Biophys Res Commun. 369(3):977-81 [PDF] [Cited by 62]

2007

Targeting TACE-dependent EGFR ligand shedding in breast cancer. Kenny PA and Bissell MJ (2007)  J Clin Invest 117 (2) 337-345 [PDF] [Cited by 253]

Tackling EGFR signaling with TACE inhibitors: a rational target for metalloproteinase inhibitors in cancer. Kenny PA (2007)  Expert Opinion on Therapeutic Targets 11(10):1287-1298 [PDF] [Cited by 34]

3D extracellular matrix culture models of EGFR signaling and drug response. Kenny PA (2007)  Biochemical Society Transactions 35(4):665-668 [PDF] [Cited by 25]

TACE: a new target in EGFR-dependent tumors.Kenny PA (2007)  Differentiation 75(9) 800-808 [PDF] [Cited by 70]

ERa-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. McBryan J, Howlin J, Kenny PA, Shioda T and Martin F (2007)  Oncogene 26(44):6406-6419 [PDF] [Cited by 52]

The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ (2007)  Molecular Oncology 1(1) 84-96  [PDF] [Cited by 783]

3D culture models of normal and malignant breast epithelial cells. Lee GY, Kenny PA, Lee EH and Bissell MJ (2007)  Nature Methods 4(4):359-365 [PDF] [Cited by 1,037]

Targeting the tumor microenvironment. Kenny PA, Lee GY, and Bissell MJ (2007)  Frontiers in Bioscience 12:3468-3474 [PDF] [Cited by 190]

Fibrosis and cancer: Do myofibroblasts come from EMT? Radisky DC, Kenny PA and Bissell MJ (2007)  J Cell Biochem 101 (4):830-839. [PDF] [Cited by 306]

2006

Gene expression signature in organized and growth arrested mammary acini predicts good outcome in brest cancer. Fournier MV, Martin KJ, Kenny PA, Xhaja K, Bosch I, Yaswen P and Bissell MJ (2006).  Cancer Research 66 (14) 7095-7102 [PDF] [Cited by 125]

The Ecology of Tumors. Kenny PA, Nelson CM, Bissell, MJ (2006)  The Scientist 20 (4) 30-35 [PDF] [Cited by 16]

2005

Microenvironmental regulators of tissue structure and tumor progression – The role of matrix metalloproteinases in the loss of tissue polarity and induction of genomic instability. Cold Spring Harbor Symposia in Quantitative Biology V Bissell MJ, Kenny PA, Radisky DC (2005) ol LXX 343-356 [PDF] [Cited by 270]

Meeting Report - Keystone Symposium: The Role of Microenvironment in Tumor Induction and Progression, Banff, Canada, Feb 5th – Feb 10th 2005. Bascom JL and Kenny PA (2005)  Breast Cancer Research 7: 113-118 [PDF]

Receptor and secreted targets of Wnt/beta-catenin signaling in mouse mammary epithelial cells. Kenny PA, Enver T and Ashworth A (2005)  BMC Cancer 5 (1) 3 [PDF] [Cited by 65]

2003

Tumor reversion: Correction of malignant behavior by microenvironmental cues. Kenny PA and Bissell MJ (2003)  International Journal of Cancer (107)  688-95 [PDF] [Cited by] [Cited by 332]

Meeting Report: 42nd Annual Meeting of the American Society for Cell Biology. Kenny PA and Rizki A (2003)  Breast Cancer Research 5(3):147-53 [PDF] [Cited by 1]

2002

Retroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell line. Kenny PA, Enver T and Ashworth A (2002)  BMC Mol Biol. 3(1):13 [PDF] [Cited by 21]

1999

Molecular evolution of immunoglobulin and fibronectin domains in Titin and related muscle proteins. Kenny PA, Liston EM and Higgins DG (1999)  Gene (232) 11-23 [PDF] [Cited by 63]

 

 

Citation counts courtesy of